Research ExplorerPublicationsNeue Aspekte in der Behandlung von Schilddrüsenkarzinomen: H...

Neue Aspekte in der Behandlung von Schilddrüsenkarzinomen: Highlights vom ASCO-Kongress 2019

Standard

Neue Aspekte in der Behandlung von Schilddrüsenkarzinomen: Highlights vom ASCO-Kongress 2019. / Möckelmann, N; Betz, C.

In: HNO, Vol. 67, No. 12, 12.2019, p. 925-930.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Möckelmann, N & Betz, C 2019, 'Neue Aspekte in der Behandlung von Schilddrüsenkarzinomen: Highlights vom ASCO-Kongress 2019', HNO, vol. 67, no. 12, pp. 925-930. https://doi.org/10.1007/s00106-019-00764-5

APA

Möckelmann, N., & Betz, C. (2019). Neue Aspekte in der Behandlung von Schilddrüsenkarzinomen: Highlights vom ASCO-Kongress 2019. HNO, 67(12), 925-930. https://doi.org/10.1007/s00106-019-00764-5

Vancouver

Möckelmann N, Betz C. Neue Aspekte in der Behandlung von Schilddrüsenkarzinomen: Highlights vom ASCO-Kongress 2019. HNO. 2019 Dec;67(12):925-930. https://doi.org/10.1007/s00106-019-00764-5

Bibtex

@article{8f9653b7003f435e8034e046a943cf04,
title = "Neue Aspekte in der Behandlung von Schilddr{\"u}senkarzinomen: Highlights vom ASCO-Kongress 2019",
abstract = "The majority of patients with thyroid cancer have a remarkably good chance of cure in the context of surgical treatment, due to their mostly local tumor spread. However, a small proportion of patients with advanced and metastatic thyroid tumors usually require multimodality treatment. Abstracts from the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting are summarized in this review, to provide insights into current aspects of thyroid carcinoma treatment. In addition to innovations in the treatment of radioiodine-refractory differentiated and medullary thyroid carcinoma, current approaches to anaplastic thyroid carcinoma are presented and critically interpreted.",
keywords = "Combined Modality Therapy, Congresses as Topic, Humans, Immunotherapy, Iodine Radioisotopes, Thyroid Neoplasms/therapy",
author = "N M{\"o}ckelmann and C Betz",
year = "2019",
month = dec,
doi = "10.1007/s00106-019-00764-5",
language = "Deutsch",
volume = "67",
pages = "925--930",
journal = "HNO",
issn = "0017-6192",
publisher = "Springer",
number = "12",

}

RIS

TY - JOUR

T1 - Neue Aspekte in der Behandlung von Schilddrüsenkarzinomen: Highlights vom ASCO-Kongress 2019

AU - Möckelmann, N

AU - Betz, C

PY - 2019/12

Y1 - 2019/12

N2 - The majority of patients with thyroid cancer have a remarkably good chance of cure in the context of surgical treatment, due to their mostly local tumor spread. However, a small proportion of patients with advanced and metastatic thyroid tumors usually require multimodality treatment. Abstracts from the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting are summarized in this review, to provide insights into current aspects of thyroid carcinoma treatment. In addition to innovations in the treatment of radioiodine-refractory differentiated and medullary thyroid carcinoma, current approaches to anaplastic thyroid carcinoma are presented and critically interpreted.

AB - The majority of patients with thyroid cancer have a remarkably good chance of cure in the context of surgical treatment, due to their mostly local tumor spread. However, a small proportion of patients with advanced and metastatic thyroid tumors usually require multimodality treatment. Abstracts from the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting are summarized in this review, to provide insights into current aspects of thyroid carcinoma treatment. In addition to innovations in the treatment of radioiodine-refractory differentiated and medullary thyroid carcinoma, current approaches to anaplastic thyroid carcinoma are presented and critically interpreted.

KW - Combined Modality Therapy

KW - Congresses as Topic

KW - Humans

KW - Immunotherapy

KW - Iodine Radioisotopes

KW - Thyroid Neoplasms/therapy

U2 - 10.1007/s00106-019-00764-5

DO - 10.1007/s00106-019-00764-5

M3 - SCORING: Review

C2 - 31628529

VL - 67

SP - 925

EP - 930

JO - HNO

JF - HNO

SN - 0017-6192

IS - 12

ER -